Moderate

Cutaneous leishmaniasis

CL · Infectious Disease
Physician-written · Verified by three sets of doctors · Reviewed November 2026

Bedside summary

Cutaneous leishmaniasis, from sandfly-transmitted Leishmania species, causes chronic skin ulcers that may self-heal but scar, with risk of mucosal spread (New World species). Treatment choice depends on species, lesion number/site and host.

Red flags

  • Mucosal involvement (nasal/oropharyngeal - New World)
  • Extensive/disfiguring facial lesions
  • Immunosuppression with disseminated disease
  • Antimonial cardiotoxicity (QT prolongation)
  • Secondary bacterial sepsis

Assessment

Differential diagnosis

  • Chronic bacterial/fungal skin ulcer
  • Cutaneous tuberculosis / atypical mycobacteria
  • Skin malignancy (SCC/BCC)
  • Sporotrichosis
  • Tropical ulcer / pyoderma

Investigations

  • Skin scraping/slit-skin smear and tissue for microscopy (amastigotes)
  • PCR for species identification
  • Culture (specialised)
  • Travel history for Old World vs New World species
  • Assess for mucosal involvement (New World)
  • Biopsy to exclude malignancy if atypical

Management

  • Take exposure history and localise/count lesions
  • Confirm with microscopy and species-level PCR (guides mucosal risk and therapy)
  • Assess whether local or systemic therapy is appropriate
  • For simple Old World lesions, consider local therapy or observation if self-healing expected
  • Use systemic therapy for complex, multiple, facial, or New World (mucosal-risk) disease
  • Choose agent by species and local resistance patterns
  • Monitor for drug toxicity (cardiac, renal, pancreatic with antimonials)
  • Treat and prevent secondary bacterial infection
  • Follow lesions to healing and watch for mucosal spread
  • Provide wound care and scar management
  • Counsel on sandfly avoidance
  • Specialist tropical medicine input for complex cases

Drugs & doses

Liposomal amphotericin B (e.g. 3 mg/kg IV on days 1-5, 10 - species-dependent regimens)
Pentavalent antimony (sodium stibogluconate) 20 mg/kg/day IV/IM for 20 days (where used)
Miltefosine 2.5 mg/kg/day PO (max 150 mg/day) for 28 days
Intralesional antimony or cryotherapy/thermotherapy for simple Old World lesions

Disposition

Outpatient tropical medicine/dermatology; admit for systemic therapy if toxic agents or severe disease.

Complications & pitfalls

  • Mucocutaneous leishmaniasis (destructive)
  • Disfiguring scarring
  • Secondary bacterial infection
  • Drug toxicity (cardiac, renal, pancreatic)
  • Relapse/chronicity in immunosuppression

Exam pearls

  • Species identification drives therapy and mucosal-risk assessment
  • Many Old World lesions self-heal - weigh treatment toxicity against benefit
  • New World species carry mucocutaneous risk - lower threshold for systemic therapy
  • Miltefosine is teratogenic - ensure contraception
  • Monitor ECG and biochemistry with pentavalent antimonials

Disclaimer: Educational decision support for qualified clinicians and students — not a substitute for clinical judgement, local protocols or a full drug reference. Confirm every dose and contraindication against your formulary before prescribing.